Fms-like tyrosine kinase 3 （FLT-3） is a cytokine receptor expressed on the surface of bone-marrow progenitor of hematopoietic cells. FLT-3 ligands （FLT-3L） are produced by peripheral blood mononuclear cells, and found in various human body fluids. FLT-3L is a cytokine that promotes the survival, proliferation, and differentiation of hematopoietic progenitors in synergy with other growth factors, such as stem cell factor. FLT-3 signal is involved in the regulation of vessel formation as well as B cell differentiation, suggesting that FLT-3 signal contributes to the pathogenesis of vascular abnormalities and immune dysregulation in rheumatic diseases. The FLT-3L plays a role in complex cytokine interactions in the process of proliferation and differentiation of various hematologic periods while it is a router in early cell interactions. The FLT-3 receptor is a transmembrane protein that reaches its biologically active form by proteolytic lysis. It was suggested that with its proliferative activity, the FLT-3L also has an antitumor effect. The FLT-3L is an earlier releaser of the progenitor cells from the stem cell pool according to GM-CSF and G-CSF actions, which occur later. Additionally, a study on mouse models showed that the FLT-3L increases the blood amount of CD34 cells. These features gave rise to the idea that recombinant FLT-3L could be used in bone marrow transplantation to evoke cell mobilization. Similarly, some authors theorized that the FLT-3L could be used in many pathological diseases such as Fanconi and aplastic anemia that originated from stem cell defects.